MustangBio
    • About
      • About Mustang Bio
      • Leadership
      • Board of Directors
      • In the News
      • Contact
    • Our Approach
      • Our Approach
      • About CAR T Cell Therapy
      • Publications
    • Pipeline
      • Pipeline
      • Clinical Trials
    • Partnering
      • Partnering
      • Active Collaborations
    • Careers
    • Investor Relations
      • News & Events
      • Company Info
      • Financial Info
      • Stock Data
      • SEC Filings
      • Governance

    Press Releases

    Investors

    Investors

    • Overview
    • News & Events
      • Overview
      • Press Releases
      • IR Calendar
      • Email Alerts
    • Company Info
      • Overview
      • Management Team
      • Presentations
      • Contacts
      • FAQ
    • Financial Info
      • Overview
      • Financial Results
      • Income Statement
      • Balance Sheet
      • Cash Flow
    • Stock Data
      • Quote
      • Charts
      • Historical Data
    • SEC Filings
      • Overview
      • All SEC Filings
      • Annual Reports
      • Quarterly Reports
      • Section 16 Filings
    • Governance
      • Overview
      • Board of Directors
      • Board Committees
      • Governance Documents
    • News & Events

    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
    November 2, 2023

    Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meeting

    October 30, 2023

    Mustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

    October 26, 2023

    Mustang Bio Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

    October 26, 2023

    Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma

    September 7, 2023

    Mustang Bio to Participate in Upcoming September 2023 Investor Conferences

    August 16, 2023

    Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy

    August 14, 2023

    Mustang Bio Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

    August 3, 2023

    Mustang Bio to Participate in Two August 2023 Investor Conferences

    July 31, 2023

    Mustang Bio Announces Amendment and Closing of Strategic Manufacturing Partnership Transaction with uBriGene (Boston) Biosciences

    July 6, 2023

    Mustang Bio Announces Participation in Upcoming Scientific Meetings

    • arrow_back
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • …
    • 19
    • arrow_forward
    rss_feed News RSS
    • Email Alerts
    • Contacts
    • RSS News Feed

    95 Sawyer Road, Suite 110 • Waltham, MA 02453

    781-652-4500 info@mustangbio.com

    Twitter Linkedin

    © Copyright 2025 Mustang Bio